Background A simple and inexpensive sarcopenia screening tool would be beneficial in clinical practice. This study was performed to determine whether SARC-F questionnaire can be used to identify physical limitations and poor prognosis in elderly cardiovascular disease (CVD) patients.
Introduction
Sarcopenia is a syndrome characterized by age-related loss of skeletal muscle mass and physical function, which is responsible for frailty, disability, falls, and poor prognosis [1] [2] [3] . The incidence of sarcopenia will most likely increase over the next 40 years due to the aging of the world's population [1] , as its prevalence rate is known to increase with age [4] . In addition to increased risk of cardiovascular disease (CVD) in the community-dwelling elderly population [5] , sarcopenia was also reported to be related to adverse outcomes in elderly patients with CVD [6] [7] [8] . Sarcopenia is now recognized as a distinct disease entity with its own ICD-10-CM code (M62.84) [9] , and sarcopenia in the elderly is becoming an increasingly important issue in cardiovascular medicine [10, 11] .
SARC-F questionnaire is a screening tool used for rapid assessment of sarcopenia status, which does not require special measurements or equipment [12, 13] . The performance of this questionnaire in identifying elderly people with impaired physical function and sarcopenia was reported to be comparable to more rigorous tests [14] [15] [16] [17] , and it showed good predictive capabilities for physical limitations and mortality in the community-dwelling elderly population [18] [19] [20] [21] . Previously, we reported that SARC-F was a useful screening tool for impaired physical function in hospitalized elderly CVD patients [22] . Despite the strong predictive capability of physical functional impairment for readmission and mortality [23] [24] [25] , there have been no previous studies regarding the prognostic value of SARC-F in elderly CVD patients. The present study was therefore performed to determine whether SARC-F can be used to identify physical limitations and predict poor prognosis in elderly CVD patients.
Methods
This study involved a retrospective review of 257 consecutive Japanese patients ≥65 years old admitted to the Cardiovascular Center, Kitasato University Hospital, for CVD that were examined by SARC-F and evaluation of physical function between September 2015 and July 2016. Patients that were unable to walk were excluded from the study. The study protocol was approved by the Ethics Committee of Kitasato University Hospital, and informed consent was obtained from all patients.
The characteristics of the patients, including age, sex, body mass index (BMI), and clinical details of presentation (living status, comorbidities, and medication use), as well as demographic, echocardiographic, and biochemical data just prior to hospital discharge, along with information on adverse events after hospital discharge were recorded from electronic medical records. The estimated glomerular filtration rate (eGFR) was defined according to the Japanese Society of Nephrology formula: 194 × (serum creatinine) 1.094 × (age) 0.287 for men and 194 × (serum creatinine) 1 .094 × (age) 0.287 × 0.739 for women [26] . Comorbidity score was calculated by assigning a value of 1 point to each of the following conditions: atrial fibrillation, diabetes, hypertension, dyslipidemia, chronic kidney disease (eGFR <60 mL/min/1.73 m 2 ), stroke, and anemia (hemoglobin <13.0 g/dL for men and <12.0 g/dL for women).
At the time of hospital discharge, the patients were asked to complete the SARC-F questionnaire, which has five components: strength, assistance in walking, rise from a chair, climb stairs, and falls (Table 1) [13] . The SARC-F scores ranged from 0 to 10, with 0 -2 points for each component (0 = best to 10 = worst); patients with a total score of ≥4 were classified as having a risk of sarcopenia [15] . The original version of SARC-F was adapted for use in Japanese [22] . SARC-F has been shown to have good test-retest reliability [27] , and high specificity but low sensitivity for classification of sarcopenia in older adults [15, 18] .
Physical function was evaluated and electrocardiographic data were monitored continuously via telemetry at discharge from hospital. Handgrip strength was measured using a digital dynamometer (TKK 5101 Grip-D; Takei, Tokyo, Japan) with the patient in the sitting position. data on two maximal isometric voluntary contractions of the hands for 3-s each with the elbow joint fixed at 90° flexion were collected for both hands, and the greatest strength, expressed as absolute value (kg), was used in the analyses. The short physical performance battery (SPPB) consisting of three components (usual gait speed, repeated chair stands, standing balance) was measured according to the established methods [28] . SPPB scores ranged from 0 to 12, i.e., 0-4 points for each component (0 = worst to 12 = best). The 6-minute walking distance (6MWD) was determined according to the guidelines established by the American Thoracic Society [29] . Patients received standardized instructions to cover as much distance as possible within the allotted time, and were allowed to use assistive devices for the walking test.
The endpoint in this study was set as the first occurrence of all-cause emergency readmission or all-cause mortality, and the time to the endpoint was calculated as the number of days from the date of hospital discharge to the date of the event.
The results of normally distributed continuous variables are expressed as the means ± standard deviation, and variables not normally distributed are presented as medians (interquartile range). Categorical variables are expressed as numbers and percentages. The patients were divided into two groups according to SARC-F score: SARC-F <4 and SARC-F ≥4 [15] . The unpaired Student's t test, Mann-Whitney U test, and Fisher's exact test were used to compare the baseline patient characteristics and physical function between the two groups as appropriate. A number of physical function outcome measures at hospital discharge-i.e., low handgrip strength (<26 kg for males and <18 kg for females), slow gait speed (≤0.8 and ≤1.0 m/s), low SPPB score (≤8 points), and short 6MWD (<300 and <400 m)-were examined according to SARC-F score by logistic regression analyses with adjustment for age, sex, and BMI as potential confounders [30] . Adjusted odds ratios (ORs) are reported with corresponding 95% confidence intervals (95% CI). The endpoint of first occurrence of all-cause emergency readmission or death was evaluated using the Kaplan-Meier method and compared by the log-rank test. The relations between SARC-F score and adverse events after discharge were evaluated by Cox regression analyses with adjustment for age, sex, BMI, living status, and comorbidity score. Hazard ratios (HRs) are reported with corresponding 95% CI. Receiver-operating characteristic (ROC) curves for endpoint of first emergency readmission or death were used to compare the accuracy of adding physical function to SARC-F score to determine whether physical function complemented the predictive ability of the SARC-F score. The areas under the curves (AUCs) were compared according to the method of DeLong et al. [31] . Statistical analyses were performed using SPSS version 23.0 (IBM Corporation, Armonk, NY) and R version 3.2.1 (R Foundation for Statistical Computing, Vienna, Austria). Two-tailed P <0.05 was taken to indicate statistical significance. Table 2 shows the baseline characteristics, SARC-F, and physical function of all patients and for groups stratified by SARC-F score. The gender distribution of the study population was 65.0% male/35.0% female, with a mean age of 75.8 ± 6.5 years, and 41.2% had heart failure, 36.2% had coronary artery disease, and 22.6% had other clinical entities. At discharge, beta-blockers were prescribed in 82.1% of cases, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in 75.1%, and statins in 69.3%. The median SARC-F score in the total patient population was 2, and 26.8% had SARC-F score ≥4. Relative to patients with SARC-F <4, those with SARC-F ≥4 were older and had a higher prevalence of comorbidities. Physical function was consistently poorer in the SARC-F score ≥4 group, and this groups had significantly higher percentages of patients with low handgrip strength and SPPB score, slow gait speed, and short 6MWD than the SARC-F score <4 group (Table 2) . Table 3 shows the results of logistic regression analyses. SARC-F ≥4 showed an independent association with physical limitations. All components of SARC-F also showed significant associations with physical limitations.
Results
In the present study, the prevalence rate of SARC-F ≥4 was 26.8% and increased significantly with age from 18.9% in patients 65-74 years old to 32.9% in those ≥75 years old (P = 0.015) (Figure 1 ). The prevalence rate of SARC-F ≥4 also increased with comorbidities from 17.5% in patients with none to two comorbidities, 27.7% in those with three to four comorbidities, and 37.9% in those with five to seven comorbidities (P trend = 0.007).
A total of 60 (23.3%) patients were readmitted to hospital and 17 (6.6%) died during a median follow-up period of 11 months (interquartile range: 6-13 months). The rates of adverse events were significantly higher in the SARC-F ≥4 group compared to the SARC-F <4 group (log rank, P = 0.009) (Figure 2 ). SARC-F score was a significant and independent predictor of first emergency readmission or death in our study population, even after adjusting for age, sex, BMI, living status, and comorbidity score (Table 4) . On multivariate Cox regression analysis, SARC-F ≥4 was shown to be associated with a 1.78-fold increase in risk of adverse events (95% CI: 1.03-3.07; P = 0.040). Furthermore, the relations between SARC-F score and endpoint of first occurrence of all-cause emergency readmission or death within 90 and 180 days after hospital discharge were examined. Even after adjusting for age, sex, BMI, living status, and comorbidity score, SARC-F score and SARC-F ≥4 showed similar associations with adverse events within 90 and 180 days after discharge ( Table 4 ). The logistic regression models of SARC-F score only and SARC-F score + physical function were subjected to ROC curve analysis, as shown in Table  5 . The AUCs on ROC curve analysis were greater with addition of usual gait speed, SPPB, or 6MWD to SARC-F, although the differences were not statistically significant. Values are expressed as means ± SD, n (%), or medians (interquartile range).
6MWD, 6-minute walking distance; ACE inhibitor, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; SBP, systolic blood pressure; SPPB, short physical performance battery. 
Discussion
In our study population, 26.8% of patients had SARC-F score ≥4, indicating a risk of sarcopenia, and the prevalence of SARC-F ≥4 increased with both age and comorbidities. The degrees of physical limitations were more severe in the SARC-F ≥4 group compared to the SARC-F <4 group. Elderly patients hospitalized for CVD with SARC-F ≥4 had a higher risk of readmission or death after hospital discharge than those with SARC-F <4. Thus, SARC-F was suggested to be a useful screening tool for risk stratification in hospitalized elderly CVD patients.
Consistent with previous reports, the prevalence of SARC-F ≥4 increased with age, and the rate among CVD patients was higher than that in the general community-dwelling elderly population in the present study [17] [18] [19] 21] . The prevalence of SARC-F ≥4 also increased with number of comorbidities in our cohort. There are multiple etiological mechanisms underlying the development of sarcopenia with age [32, 33] . Patients with muscle loss associated with the development of various diseases show accelerated loss of muscle mass and strength [34] , and hospitalization itself has been shown to adversely affect physical function [35] . Both muscle mass and strength have been shown to be related to circulating inflammatory markers in patients with chronic diseases [36, 37] . Therefore, increased awareness and the development of preventive strategies for sarcopenia, comorbidities, and general health status, as well as cardiovascular status, in hospitalized elderly CVD patients.
Consistent with previous observations [22] , SARC-F ≥4 was related to physical limitations in elderly CVD patients, including reduced handgrip strength, gait speed, SPPB, and 6MWD, all of which were reported to be strong predictors of quality of life, mobility, hospitalization, and mortality [23] [24] [25] 38, 39] . Moreover, SARC-F ≥4 was associated with higher probabilities of physical function measurements below critical cut-off values, including gait speed ≤1.0 m/s and 6MWD <400 m, indicating limited mobility [39] . These observations suggest that SARC-F is useful for identifying patients with physical limitations that require treatment.
The results presented here indicated that SARC-F can be used to predict first occurrence of all-cause emergency readmission or all-cause mortality after hospital discharge in elderly CVD patients. In several recent studies, SARC-F was shown to have performance equivalent to more rigorous definitions for predicting adverse outcomes in community-based elderly populations [15, 18, 21] . Sarcopenia diagnosed according to the standard definitions was shown to be associated with increased rates of hospital readmission and mortality in hospitalized elderly patients [40, 41] . To our knowledge, this is the first report regarding the prognostic value of SARC-F in elderly CVD patients. In addition, although not statistically significant, the AUCs for adverse events after discharge were higher when usual gait speed, SPPB, or 6MWD was added to SARC-F in the present study. These results suggested that a multi-item measure including physical function outperformed SARC-F alone in elderly patients hospitalized with CVD. However, if there is no time to carry out physical function measures in a busy ward, SARC-F is recommended as a screening tool for predicting the prognosis in this population.
Risk stratification after hospitalization for CVD is important with regard to planning of medical care as well as to improve the prognosis of vulnerable populations. One of the most important reasons for assessing sarcopenia status, including impaired physical function, is the fact that this is an at least partially reversible condition. Previous studies have shown that improved physical function is associated with lower risk of adverse events in CVD patients [42, 43] . Therefore, methods for the rapid and accurate assessment of sarcopenia status are important to facilitate treatment with various interventions, including cardiac rehabilitation, resistance and aerobic exercise, nutritional recommendations, reduction of polypharmacy (if possible), and self-care [4, 44] . These interventions could ameliorate adverse outcomes after discharge in elderly CVD patients determined to be at risk of sarcopenia. Previous studies indicated that SARC-F has a low false positive rate in the diagnosis of sarcopenia [15, 18] . Therefore, SARC-F represents a simple and rapid screening tool for clinical use to assess sarcopenia status, and it may be useful in predicting the prognosis of hospitalized elderly CVD patients.
This study had several limitations. First, this was a single-center study with a small patient population and limited follow-up. In addition, this was a retrospective study, and therefore the accuracy of some variables relied on the accuracy of medical records. Second, as patients that were unable to walk were excluded from the analysis, the prevalence of sarcopenia may have been underestimated in our study population. Third, as we did not evaluate muscle mass, it was not possible to compare SARC-F to standard definitions of sarcopenia. Finally, this study was conducted only in Asian patients hospitalized for CVD. Therefore, further studies are needed for validation of SARC-F in other populations and in comparison with standard definitions of sarcopenia.
